Connect with us


Aurora Cannabis increased its net income despite pandemic

The effect of the pandemic containment was reflected in cannabis sales, which increased 32% to $69.6 million. Aurora Cannabis reported, on May 14th, a 16% increase in its net income, to $75.5 million from $56 million. Cannabis 2.0 products represent one-fifth of Aurora Cannabis’ recreational sales, which increased by 24%. However, it reported a net loss of $98.6 million in the January-March period.



This picture show a person selling cannabis.

Almost all the world’s economic indicators are negative during the pandemic, both for companies and for States. Nor are the stock market indicators as expected, except for specific counts. One of them is the cannabis giant Aurora Cannabis, which, according to the El Ceo report, is finding an opportunity in the current crisis.

The Aurora Cannabis shares scored their best day in more than two years, transferring an increase in cannabis sales in its third fiscal quarter of 2020 ending in March, due to the confinement caused by the COVID-19 pandemic.

The company’s shares rose 65.32% on the Toronto Stock Exchange on Monday, May 18th, to $15.35, its best performance since April 2018, and its highest level since March 30th of this year. However, not everything is rosy at the corporation, which has its headquarters in the city of Edmonton.

Aurora’s market value has fallen more than 60% since January, due to the company’s internal problems and a series of acquisitions that have lost value. In February, the cannabis company announced the layoff of 500 employees and the departure of its former CEO, Terry Booth.

Find out more details about the financial situation of Aurora Cannabis and read the latest cannabis news with the mobile app.

Aurora Cannabis registered a huge increase in income

The report on Aurora Cannabis’s shares came after the Canadian company reported last Thursday, May 14th, a 16% increase in its net income to $75.5 million from $56 million in the immediately preceding period, exceeding analysts’ expectations.

“I am incredibly proud of the Aurora team for working through these difficult times to maintain uninterrupted operations at all of our production facilities and to meet the needs of our patients and consumers,” said Aurora’s interim CEO, Michael Singer.

The effect of the pandemic containment was reflected in cannabis sales, which increased 32% to $69.6 million. The increase in sales was due to cannabis being an essential service in some regions of the United States and Canada.

In the United States, most of the 33 states with medical or recreational cannabis markets ranked the cannabis business in this category.

The “Cannabis 2.0” portfolio, which includes steaks, gummi bears, chocolates and drinks, is a product that customers are rushing to reduce before government restrictions are in place. They represent one-fifth of Aurora Cannabis’ recreational sales, which increased by 24%.

Aurora Cannabis is still operating at a loss

However, Aurora reported a net loss of $98.6 million (CAD137 million) in the January-March period. The company said it estimates it will be profitable in the next fiscal year and double its aircraft to keep capital expenditures below $72 million (CAD100 million) in the second half of the year.

Nevertheless, between January and March, Aurora achieved a turnover of about $54 million, compared to about $40 million in the previous quarter.

According to the company, it was seen that some consumers have welcomed the advance of COVID-19 and the beginning of the confinement measures in the United States. Aurora, established in 2006, still operates at a loss, but with increased sales and a cutback in expenses in the last quarter, it expects to make a profit soon.

Canopy Growth, its big competitor and the largest company in the cannabis sector by market capitalization, also rose strongly on Wall Street this Friday, May 15th,  and its shares end up with a 14.43% rise.


(Featured image by altika via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in LA MARIHUANA, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Helene Lindbergh is a published author with books about entrepreneurship and investing for dummies. An advocate for financial literacy, she is also a sought-after keynote speaker for female empowerment. Her special focus is on small, independent businesses who eventually achieve financial independence. Helene is currently working on two projects—a bio compilation of women braving the world of banking, finance, crypto, tech, and AI, as well as a paper on gendered contributions in the rapidly growing healthcare market, specifically medicinal cannabis.